» Articles » PMID: 17103065

Prognostic Factors in Papillary and Follicular Thyroid Carcinoma: Their Implications for Cancer Staging

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 2006 Nov 15
PMID 17103065
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC) are two distinct histological types of thyroid carcinoma but have often been studied and staged as a collective group, known as differentiated thyroid carcinoma (DTC). However, this may not be an optimal approach to cancer staging.

Methods: A total of 760 patients with DTC, comprising 589 (77.5%) with PTC and 171 with (22.5%) FTC, being managed at our institution from 1961 to 2001 were retrospectively reviewed. Their clinicopathological features, treatment modalities received, and postoperative outcome were analyzed. Both univariate and multivariate analyses were performed to identify prognostic factors related to cancer-specific survival (CSS) for PTC and FTC.

Results: There were statistically significant differences between PTC and FTC in terms of age >/=50 years at diagnosis (P = .040), tumor size (P < .001), lymph node metastases (P < .001), distant metastases (P < .001), extrathyroidal extension (P < .001), multifocality (P = .002), capsular invasion (P < .001), extent of thyroid resection (P < .001), radioiodine ablation (P < .001), and external-beam irradiation (P = .003). Although PTC and FTC had similar 10-year and 15-year CSS (P = .846), each possessed its own set of independent prognostic factors for CSS. Age at diagnosis and completeness of resection were independent prognostic factors in both PTC and FTC.

Conclusions: There were marked differences in clinicopathologic features, treatment, and prognostic factors between the two histologic types of DTC. Different staging systems should be evaluated and validated for PTC and FTC individually in the future.

Citing Articles

Comprehensive transcriptomic profiling reveals molecular characteristics and biomarkers associated with risk stratification in papillary thyroid carcinoma.

Yan C, Zheng C, Luo J, Wu X, Meng X, Lv C J Pathol Clin Res. 2025; 11(2):e70022.

PMID: 40001321 PMC: 11860273. DOI: 10.1002/2056-4538.70022.


Genome-wide transcriptome analysis and drug target discovery reveal key genes and pathways in thyroid cancer metastasis.

Zou M, Qattan A, Al-Alwan M, Ghebeh H, Binjumah N, Al-Haj L Front Endocrinol (Lausanne). 2025; 16:1514264.

PMID: 39996058 PMC: 11847698. DOI: 10.3389/fendo.2025.1514264.


Dynamic estimates of survival in patients with follicular thyroid cancer: a retrospective cohort study.

Ji X, Yu R, Sun W, Zhang P, Dong W, Zhang H Endocrine. 2024; 87(2):627-634.

PMID: 39313705 DOI: 10.1007/s12020-024-04010-z.


Development and validation of a lung metastases-predicting nomogram for intermediate- to high-risk differentiated thyroid carcinoma patients.

Ma W, Yu F, Chen B, Yang Z, Kang F, Li X Future Oncol. 2024; 20(22):1575-1586.

PMID: 38868921 PMC: 11457604. DOI: 10.1080/14796694.2024.2354161.


Guiding the postoperative radioactive iodine-131 therapy for patients with papillary thyroid carcinoma according to the prognostic risk groups: a SEER-based study.

Yang Y, Gan M, Yi K, Han S, Lin Z, Shi Y J Cancer Res Clin Oncol. 2023; 149(19):17147-17157.

PMID: 37782329 DOI: 10.1007/s00432-023-05299-5.